Annovis Bio, Inc.
NYSE:ANVSBiotechnology
+$0.00 today
- Market cap
- $51.64M
- Beta
- 1.24
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.47
Volume 1.35M
Average 1.08M
ANVS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Annovis Bio, Inc.NYSE: ANVS
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $16.72B rose 333538.7% year over year, ahead of the +90463.6% change in trailing-twelve-month research & development. Sequentially, it rose 190968.1% from the prior quarter. Over 3 fiscal years it compounded at +15.1% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +333538.7% holds above the trailing-twelve-month pace of +90463.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 25.22M USD
- Year-over-year change
- +26.1%
- 4-year CAGR
- +31.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 25.22M | +26.1% |
| FY2024 | 2024-12-31 | 20M | -48.5% |
| FY2023 | 2023-12-31 | 38.79M | +134.9% |
| FY2022 | 2022-12-31 | 16.52M | +94.8% |
| FY2021 | 2021-12-31 | 8.48M | — |
Research & Development vs competitors
How ANVS compares with its peers on the latest reported figures
- ANVS's LTM Mar 2026 research & development of $16.74B is the highest of the 6 companies compared; the peer median is $16.65M.
- Its year-over-year change of +90463.6% is the highest of 6, against a peer median of -13.6%.
- Over three fiscal years its annual growth of +15.1% compares with a peer median of -5.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $16.74B | +90463.6% | +15.1% | — | |
| LTM Mar 2026 | $23.45M | -1.8% | -5.3% | — | |
| LTM Jun 2026 | $18.74M | -30.0% | -3.0% | 53.4% | |
| LTM Mar 2026 | $16.65M | -23.2% | -13.5% | — | |
| LTM Dec 2025 | $15.03M | -13.6% | -42.3% | 56.6% | |
| LTM Mar 2026 | $14.87M | +36.6% | +1076.5% | — | |
| Peer median (excluding ANVS) | $16.65M | -13.6% | -5.3% | 55.0% | |
Competitors are the stored peer set for ANVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 8.48M | 16.52M | 38.79M | 20M | 25.22M |
| Selling, General & Admin | 6.06M | 9M | 6.24M | 6.7M | 4.48M |
| Operating Expenses | 14.54M | 25.51M | 45.04M | 26.69M | 29.7M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| EBITDA | (14.5M) | (25.33M) | (56.2M) | (22.74M) | (28.85M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (14.54M) | (25.51M) | (45.04M) | (26.69M) | (29.7M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 13.34K | 182.71K | 667.9K | 331.85K | 699.06K |
| Interest Expense | 0 | 0 | 0 | 1.85M | 0 |
| Other Income / Expenses | 50.09K | 182.71K | (11.17M) | 2.1M | 841.06K |
| Income Before Tax | (14.49M) | (25.33M) | (56.2M) | (24.59M) | (28.85M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (14.49M) | (25.33M) | (56.2M) | (24.59M) | (28.85M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.90) | (3.10) | (6.23) | (2,018.50) | (1.40) |
| EPS (Diluted) | (1.90) | (3.10) | (6.23) | (2,009.77) | (1.40) |
| Weighted Avg Shares | 7.63M | 8.16M | 9.02M | 12.18M | 20.55M |
| Weighted Avg Shares (Diluted) | 7.63M | 8.16M | 9.02M | 12.24M | 20.55M |
Annovis Bio, Inc.
NYSE:ANVS
Intrinsic Alpha fair value
Locked
Current Price
$1.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.